PT - JOURNAL ARTICLE AU - Colin Holtze AU - Kevin Flaherty AU - Michael Kreuter AU - Fabrizio Luppi AU - Teng Moua AU - Carlo Vancheri AU - Mary B. Scholand TI - Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases AID - 10.1183/16000617.0078-2018 DP - 2018 Dec 31 TA - European Respiratory Review PG - 180078 VI - 27 IP - 150 4099 - http://err.ersjournals.com/content/27/150/180078.short 4100 - http://err.ersjournals.com/content/27/150/180078.full SO - EUROPEAN RESPIRATORY REVIEW2018 Dec 31; 27 AB - There are over 200 interstitial lung diseases (ILDs). In addition to patients with idiopathic pulmonary fibrosis (IPF), a percentage of patients with other ILDs also develop progressive fibrosis of the lung during their disease course. Patients with progressive-fibrosing ILDs may show limited response to immunomodulatory therapy, worsening symptoms and lung function and, ultimately, early mortality. There are few data for ILDs that may present a progressive fibrosing phenotype specifically, but we believe the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF. This review discusses the burden of ILDs that may present a progressive fibrosing phenotype and the factors impacting healthcare utilisation.Data for ILDs with a progressive fibrosing phenotype are lacking, but the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF http://ow.ly/Eoht30mS4Nx